Q3 EPS Estimate for Allurion Technologies Raised by Analyst

Allurion Technologies Inc. (NYSE:ALUR) – Equities research analysts at Roth Capital boosted their Q3 2025 earnings estimates for shares of Allurion Technologies in a report issued on Wednesday, November 13th. Roth Capital analyst J. Wittes now anticipates that the company will earn ($0.13) per share for the quarter, up from their previous estimate of ($0.14). Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Allurion Technologies’ current full-year earnings is ($0.40) per share. Roth Capital also issued estimates for Allurion Technologies’ Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.54) EPS and FY2026 earnings at ($0.29) EPS.

ALUR has been the topic of a number of other reports. Chardan Capital cut Allurion Technologies from a “buy” rating to a “neutral” rating in a report on Thursday. Roth Mkm started coverage on shares of Allurion Technologies in a research report on Friday, September 6th. They set a “buy” rating and a $2.00 price objective on the stock. Finally, TD Cowen assumed coverage on shares of Allurion Technologies in a research report on Wednesday, October 2nd. They set a “buy” rating and a $2.00 target price for the company. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $2.88.

Allurion Technologies Stock Down 14.3 %

Shares of Allurion Technologies stock opened at $0.34 on Monday. Allurion Technologies has a 52 week low of $0.31 and a 52 week high of $4.54. The stock’s 50-day simple moving average is $0.67 and its 200-day simple moving average is $1.03. The company has a market capitalization of $22.08 million, a price-to-earnings ratio of -0.71 and a beta of -0.37.

Institutional Investors Weigh In On Allurion Technologies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALUR. CVI Holdings LLC bought a new position in shares of Allurion Technologies during the 2nd quarter valued at approximately $520,000. Geode Capital Management LLC boosted its stake in Allurion Technologies by 40.7% during the third quarter. Geode Capital Management LLC now owns 516,330 shares of the company’s stock worth $317,000 after buying an additional 149,484 shares during the period. Finally, Accredited Investors Inc. increased its position in Allurion Technologies by 33.3% during the second quarter. Accredited Investors Inc. now owns 50,000 shares of the company’s stock valued at $50,000 after acquiring an additional 12,500 shares during the last quarter. 21.39% of the stock is currently owned by hedge funds and other institutional investors.

Allurion Technologies Company Profile

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.